ReviewReviews in cardiovascular medicine2026
Ankyrin Repeat Domain 1: A Key Regulatory Factor and Emerging Therapeutic Target in Heart Disease.
Review in Reviews in cardiovascular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cardiovascular disease (CVD) remains the leading cause of death worldwide, highlighting the urgent need to identify effective therapeutic targets. Ankyrin repeat domain 1 (ANKRD1), also known as cardiac ankyrin repeat protein (CARP), is a member of the muscle ankyrin repeat protein (MARP) family. The unique multi-domain cooperative mechanism and dynamic nucleocytoplasmic shuttling associated with ANKRD1 confer increasingly significant roles in the pathogenesis and progression of CVD. This review aims to summarize the current understanding of the molecular structure of ANKRD1, elucidate the mechanisms underlying key cardiovascular pathological processes, including myocardial remodeling, cardiomyopathy, cardiac development, myocardial infarction, and heart failure, and comprehensively evaluate its potential as a therapeutic target. Furthermore, this review aims to provide new theoretical foundations and future research directions for the precision diagnosis and treatment of CVD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.